AG 1296 is a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine kinase activity. It is widely used in research to study signaling pathways involved in cell proliferation, migration, and survival, particularly in vascular smooth muscle cells and fibroblasts. Due to its ability to block PDGFR-mediated responses, AG 1296 is applied in studies related to atherosclerosis, restenosis, and fibrotic diseases where PDGF signaling plays a key role. It has also been used in cancer research to investigate tumor angiogenesis and the role of stromal cells in tumor progression. In experimental models, AG 1296 helps assess the therapeutic potential of targeting tyrosine kinases in cardiovascular and oncological contexts.